(lomustine) should be administered under the supervision of a qualified physician
experienced in the use of cancer chemotherapeutic agents.
marrow suppression, notably thrombocytopenia and leukopenia, which may contribute
to bleeding and overwhelming infections in an already compromised patient,
is the most common and severe of the toxic effects of CeeNU (see
the major toxicity is delayed bone marrow suppression, blood counts should
be monitored weekly for at least 6 weeks after a dose (see
REACTIONS). At the recommended dosage, courses of CeeNU should
not be given more frequently than every 6 weeks.
bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment
must be considered on the basis of nadir blood counts from prior dose (see dosage adjustment table under
DOSAGE AND ADMINISTRATION).
(CCNU) is one of the nitrosoureas used in the treatment of certain neoplastic
CEENU (lomustine) is indicated for the following:
CeeNU has been shown to be useful as
a single agent in addition to other treatment modalities, or in established
combination therapy with other approved chemotherapeutic agents in the following:
tumors both primary and metastatic, in patients who have already received
appropriate surgical and/or radiotherapeutic procedures.
disease secondary therapy in combination with other approved drugs
in patients who relapse while being treated with primary therapy, or who fail
to respond to primary therapy.
Published Studies Related to Ceenu (Lomustine)
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. [2010.10.20]
PURPOSE: Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG... CONCLUSION: Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting. This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. [2010.03.01]
PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)... CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. [2009.12.10]
PURPOSE: The standard of care for anaplastic gliomas is surgery followed by radiotherapy. The NOA-04 phase III trial compared efficacy and safety of radiotherapy followed by chemotherapy at progression with the reverse sequence in patients with newly diagnosed anaplastic gliomas... CONCLUSION: Initial radiotherapy or chemotherapy achieved comparable results in patients with anaplastic gliomas. IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. [2007.10]
BACKGROUND AND OBJECTIVES: Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation... CONCLUSIONS: Adding lomustine to induction with idarubicin and cytarabine therapy did not statistically improve survival in elderly patients with AML. Adding intermediate-dose cytarabine to consolidation therapy did not improve outcome.
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. [2006.06.20]
PURPOSE: Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas... CONCLUSION: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma. Combined loss of 1p/19q identifies a favorable subgroup of oligodendroglial tumors. No genetic subgroup could be identified that benefited with respect to OS from adjuvant PCV.
Clinical Trials Related to Ceenu (Lomustine)
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients [Recruiting]
The goal of this clinical research study is to find the highest safe dose of lomustine
(CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM)
in the treatment of metastatic melanoma that has spread to the brain. The safety and
effectiveness of this combination therapy will also be studied.
Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients [Recruiting]
The prognosis of patients with newly diagnosed glioblastoma is dismal despite recent
therapeutic improvements Using standard therapy with temozolomide (TMZ) and radiotherapy (60
Gy), the median overall survival time (mOS) is 14. 6 months (Stupp et al., 2005). Since in a
previous non-randomized bicentric phase II trial, primary combination chemotherapy with
lomustine (CCNU) and TMZ was highly effective (mOS 23 months; UKT-03 trial; Herrlinger et
al., 2006; Glas et al., 2009) the proposed trial further investigates the efficacy of
CCNU/TMZ in a randomized multicenter phase III setting against standard therapy. In case the
projected phase III trial confirms the phase II data, CCNU/TMZ combination would be
significantly better than TMZ monotherapy and would thus be the new standard treatment for
newly diagnosed GBM patients with a methylated MGMT promotor. Thus, this trial has the
potential to profoundly change the standard therapy of this most aggressive brain tumor.
Since in the previous trial only patients with a methylated MGMT (mMGMT) promoter had a
benefit from CCNU/TMZ (mOS in the mMGMT group 34 months, in the non-mMGMT group 12. 5 months;
Glas et al., 2009) while patients with a non-methylated MGMT did not have any benefit, the
trial is restricted to mMGMT patients. The CeTeG trial randomizes in a 1: 1 fashion newly
diagnosed GBM patients (18-70 years) for either standard TMZ therapy (concomitant and 6
courses à 4 weeks of adjuvant TMZ therapy) or experimental CCNU/TMZ therapy (6 courses à 6
weeks). Both arms include standard radiotherapy (RT) of the tumor site (30 x 2 Gy). Assuming
that CCNU/TMZ therapy increases the median overall survival (mOS) from 48. 9% (standard TMZ)
to 70% (CCNU/TMZ; 75% in the previous phase II trial, Glas et al., 2009), 2 x 68 patients
have to be accrued. Patients will be accrued over 24 months and each patient will be
followed for at least 24 months adding up to a total minimal duration of the time from first
patient in until the end of the follow-up time of 48 months. The primary endpoint is overall
survival; secondary endpoints include progression-free survival, response rate, acute and
late toxicity, and quality of life.
Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old [Recruiting]
A multicenter randomized trial comparing induction therapy (IC: Idarubicin and Cytarabine, 5
+ 7) to ICL (the same drugs plus lomustine (CCNU), 200 mg/m2 orally at day 1). Patients in
complete remission (CR) will then receive a post-remission schedule with or without
lomustine according to randomization. Patients from 60 to 65 years old will be proposed to
reduced conditioning allogeneic transplantation after first consolidation.
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme [Completed]
The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor
glioblastoma multiforme (GBM) who have progression or first recurrence following initial
treatment with surgery, radiation and chemotherapy.
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) [Recruiting]
To determine whether dasatinib plus lomustine are effective for treatment of recurrent
Reports of Suspected Ceenu (Lomustine) Side Effects
Circumstance or Information Capable of Leading TO Medication Error (2),
Medication Error (1),
Retinal Exudates (1),
Platelet Count Decreased (1)
Page last updated: 2011-12-09